A Study of the Effects of Amprenavir, a Protease Inhibitor, on Carbohydrate and Fat Metabolism in HIV-Infected Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effects of a 3-drug anti-HIV regimen, amprenavir
(APV) plus abacavir (ABC) plus lamivudine (3TC), on the way carbohydrates (sugars) and fats
are metabolized (processed by the body) in HIV-infected patients who have received little or
no previous anti-HIV drug therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Glaxo Wellcome
Treatments:
Abacavir Amprenavir HIV Protease Inhibitors Lamivudine Protease Inhibitors